The prevalence of myopia has markedly increased in East and Southeast Asia, and
pathologic consequences of myopia, including myopic maculopathy and high myopia …

Presently, different types of eye diseases, such as glaucoma, myopia, infection, and dry eyes
are treated with topical eye drops. However, due to ocular surface barriers, eye drops …

Purpose (1) To compare the efficacy of continued and stopping treatment for 0.05%, 0.025%,
and 0.01% atropine during the third year.(2) To evaluate the efficacy of continued treatment …

Importance The global prevalence of myopia is predicted to approach 50% by 2050,
increasing the risk of visual impairment later in life. No pharmacologic therapy is approved …

Importance Because studies have suggested that atropine might slow the progression of
myopia in children, randomized clinical trials are warranted to understand this potential …

Purpose To evaluate the efficacy and safety of 0.05%, 0.025%, and 0.01% atropine eye
drops over 2 years to determine which is the optimal concentration for longer-term myopia …

Background Mutations in the L/M cone opsin gene array cause abnormally high perceived
retinal contrast and the development of myopia. Environmental factors may also lead to high …

In myopic eyes, pathological remodelling of collagen in the posterior sclera has mostly been
observed ex vivo. Here we report the development of triple-input polarization-sensitive …

Purpose Atropine eye drops prevent the progression of myopia, but their use has not been
tested in the Japanese schoolchildren population. Here, we evaluate the efficacy and safety …

Purpose To investigate the effect of age at treatment and other factors on treatment response
to atropine in the Low-Concentration Atropine for Myopia Progression (LAMP) Study. Design …